Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster.
Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: "On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies."
Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented:"I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company's strong foundations and drive its next phase of growth."
About Minaris Advanced Therapies:
Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.
Minaris Advanced Therapies is a portfolio company of Altaris.
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com
Media Contact:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 26, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the " Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that: The hair growth assessment (" HGA") indicators from investigators of 0.5% BID group and 1.0% BID group both experienced significant improvement from placebo group, with a significant therapeutic effect. The results showed that after the treatment of 24 weeks, compared to the placebo group, the HGA indicator of the 0.5% BID group displayed statistically significant results (P=0.000); compared to the placebo group, the HGA indicator of the 1.0% BID group displayed statistically significant results (P=0.013). The analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.
Korea Herald
12 hours ago
- Korea Herald
CLOUD MEETS AI: TERABOX REINVENTS ALL-IN-ONE AI PRODUCTIVITY PLATFORM
New toolkit streamlines one-click content creation in cloud-native space TOKYO, July 25, 2025 /PRNewswire/ -- TeraBox ("TeraBox" or "the Company"), a globally trusted cloud storage service headquartered in Tokyo, has announced the launch of a new suite of AI productivity tools, built on top of its free 1024-gigabyte cloud storage for users worldwide. With the tagline 'One Box, Infinite AI Space,' TeraBox redefines productivity as an all-in-one platform that seamlessly integrates AI-powered content creation with cloud storage, online access, and file sharing. Designed to transform raw ideas into polished, shareable outputs in minutes, TeraBox features six powerful tools: The AI Presentation Maker, TeraBox's flagship feature, generates a keynote-ready slide deck in seconds, enhanced with up-to-date insights backed by real-time data. Users simply input a prompt, paste notes, or upload a file, and TeraBox instantly creates a customizable, logically structured outline. Strapped with LLM-enhanced reasoning and professional templates, the AI Presentation Maker transforms flat information into layered, visually compelling narratives. " TeraBox is no longer just a place to store files — it's an integrated AI workspace," said Yu Furuya, product lead at TeraBox. "Everything you need is here. The AI tools are built directly on our cloud, so users no longer have to go back and forth between five different online alternatives just to find out they've wasted hours downloading and uploading across systems." Users can access TeraBox web or download the app on Android, iOS, Linux, Mac, and Windows. AI Presentation Maker, Instant Essay Writer, Live Transcriber and Smart Paraphraser are now live on web and desktop; Intelligent Search, Live Transcriber, and Versatile Scanner are live on mobile. TeraBox, developed by Flextech Inc., is a globally trusted cloud platform that combines secure storage with cutting-edge AI productivity tools. Headquartered in Tokyo, Japan, TeraBox has evolved from a robust personal cloud to a one-stop AI productivity solution that helps users create, store, and share their ideas effortlessly. With AI features like content generation and smart searching, TeraBox empowers users worldwide to work smarter, not harder. The service proudly holds ISO/IEC 27001, ISO/IEC 27701, and ISO/IEC 27018 certifications, upholding top-tier data safety and privacy standards. Download the TeraBox App on Android, iOS, Linux, Mac, and Windows devices, or visit
Korea Herald
14 hours ago
- Korea Herald
New AI Automation Platform Learns Like a Human--Infofla's Selto V2 Now Available
SEOUL, South Korea, July 25, 2025 /PRNewswire/ -- Infofla, a fast-growing AI startup specializing in workflow automation, has launched Version 2 of its flagship product 'Selto', delivering major upgrades that dramatically improve precision, flexibility, and user control. Powered by Infofla's proprietary 'VLAgent' engine—an AI system that combines large language models with advanced image recognition—Selto V2 enables businesses to automate complex digital tasks with human-like adaptability. Unlike traditional RPA (robotic process automation) tools, which often break down when unexpected screen changes occur, Selto can visually recognize and respond to real-time UI changes like pop-ups or layout modifications. "This update focuses on making automation more intuitive and flexible," said In-mook Choi, CEO of Infofla. "With Selto V2, anyone can easily design and manage automated workflows—even across unpredictable digital environments." Selto V2 introduces a new level of intelligence and flexibility for business automation. The upgraded version can now visually confirm what it has learned from screen, making it easier for users to identify and resolve issues quickly. This improvement helps boost reliability and transparency, especially in fast-changing digital environments. The platform also adapts dynamically to conditional scenarios. For instance, Selto can now tailor workflows based on different user types or interface conditions—an essential feature for customer-facing services where one-size-fits-all automation often fails. Infofla has also enhanced Selto's ability to process and reuse external data, enabling seamless input of variable information like customer names or addresses. This makes automations more scalable and personalized without increasing human workload. To support growing enterprise demand, Infofla now provides a robust administrator dashboard and has upgraded Selto's testing environment with enterprise-grade GPUs. This ensures reliable performance during large-scale Proof of Concept trials—especially in industries with high automation complexity, such as finance and insurance. Selto has already been deployed by Korea's Ministry of the Interior and Safety and top-tier e-commerce platforms. Building on that success, Infofla is currently running PoCs with major players in the financial and insurance sectors. With Selto V2, Infofla is moving beyond the limitations of existing RPA, paving the way for broader adoption of practical, accessible AI agents and positioning itself as a next-generation leader in intelligent automation. About Infofla Infofla is a Seoul-based AI software company revolutionizing workflow automation with its Vision Language Model (VLM) technology. Its proprietary solutions—including ITOMS, VLAgent, and RPACA—combine visual recognition with natural language understanding to deliver human-like adaptability in dynamic digital environments. Infofla is also developing FLAR, a robotics control system for intelligent physical automation. Its technologies are already used by Korean government and enterprise clients, and the company is expanding globally with support from partners like AWS.
